18 Chapter 1 19. Machann, W., et al., Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Eur J Heart Fail, 2011. 13(3): p. 278-83. 20. Nagano, T., et al., Myocardial fibrosis pathology in Anderson-Fabry disease: Evaluation of autopsy cases in the long- and short-term enzyme replacement therapy, and non-therapy case. Ijc Metabolic & Endocrine, 2016. 12: p. 46-51. 21. Rozenfeld, P. and S. Feriozzi, Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab, 2017. 122(3): p. 19-27. 22. Mauhin, W., et al., Innate and Adaptive Immune Response in Fabry Disease. JIMD Rep, 2015. 22: p. 1-10. 23. Birket, M.J., et al., A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology. Stem Cell Reports, 2019. 13(2): p. 380-393. 24. Namdar, M., Electrocardiographic Changes and Arrhythmia in Fabry Disease. Front Cardiovasc Med, 2016. 3: p. 7. 25. Smid, B.E., et al., Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet, 2015. 52(4): p. 262-8. 26. Arends, M., et al., Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol, 2017. 28(5): p. 1631-1641. 27. Körver, S., et al., Determinants of cerebral radiological progression in Fabry disease. Journal of Neurology, Neurosurgery & Psychiatry, 2020. 91(7): p. 756. 28. El Sayed, M., et al., Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease. Heart, 2021. 29. von Scheidt, W., et al., An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med, 1991. 324(6): p. 395-9. 30. Nakao, S., et al., An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med, 1995. 333(5): p. 288-93. 31. Sachdev, B., et al., Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation, 2002. 105(12): p. 1407-11. 32. Hoss, S., et al., Genetic Testing for Diagnosis of Hypertrophic Cardiomyopathy Mimics: Yield and Clinical Significance. Circ Genom Precis Med, 2020. 13(2): p. e002748. 33. Smid, B.E., et al., Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol, 2014. 177(2): p. 400-8. 34. Rombach, S.M., et al., Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta, 2010. 1802(9): p. 741-8. 35. Balendran, S., et al., Diagnostic strategy for females suspected of Fabry disease. Clin Genet, 2020. 97(4): p. 655-660. 36. Aquaro, G.D., et al., Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features. Diagnostics (Basel), 2022. 12(11). 37. Linhart, A., et al., Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J, 2007. 28(10): p. 1228-35. 38. Putko, B.N., et al., Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev, 2015. 20(2): p. 179-91.
RkJQdWJsaXNoZXIy MTk4NDMw